Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.400
-0.040 (-0.90%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Larimar Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -165.67 | -80.6 | -36.95 | -35.36 | -50.64 | |
| Depreciation & Amortization | 0.35 | 0.32 | 0.31 | 0.32 | 0.33 | |
| Loss (Gain) From Sale of Assets | - | - | - | - | -0 | |
| Loss (Gain) From Sale of Investments | -1.7 | -5.26 | -1.84 | -0.77 | -0.01 | |
| Stock-Based Compensation | 7 | 8.8 | 7.62 | 6.62 | 5.47 | |
| Other Operating Activities | -0.28 | -0.19 | -0.08 | -0.05 | 0.02 | |
| Change in Accounts Payable | 2.79 | 1.14 | -0.4 | 0.03 | -0.97 | |
| Change in Other Net Operating Assets | 44.31 | 5.03 | -2.11 | 1.64 | 3.71 | |
| Operating Cash Flow | -113.2 | -70.76 | -33.46 | -27.57 | -42.11 | |
| Capital Expenditures | -0.09 | -0.52 | -0.16 | -0.1 | -0.33 | |
| Investment in Securities | 100.4 | -84.87 | 33.52 | -90.86 | 24.5 | |
| Investing Cash Flow | 100.31 | -85.39 | 33.35 | -90.96 | 24.17 | |
| Issuance of Common Stock | 65.09 | 161.88 | 0.03 | 75.26 | 19.89 | |
| Financing Cash Flow | 65.09 | 161.88 | 0.03 | 75.26 | 19.89 | |
| Net Cash Flow | 52.19 | 5.74 | -0.08 | -43.27 | 1.95 | |
| Free Cash Flow | -113.29 | -71.28 | -33.62 | -27.67 | -42.44 | |
| Free Cash Flow Per Share | -1.55 | -1.16 | -0.77 | -1.07 | -2.47 | |
| Levered Free Cash Flow | -53.47 | -42.05 | -20.84 | -14.35 | -23.09 | |
| Unlevered Free Cash Flow | -53.47 | -42.05 | -20.84 | -14.35 | -23.09 | |
| Change in Working Capital | 47.1 | 6.18 | -2.51 | 1.67 | 2.73 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.